Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupog...

Amgen Inc (AMGN) has a valuation score of 67/100 (moderate), profitability score of 87/100 (strong), financial health score of 37/100 (weak), Piotroski F-Score of 7/9, Altman Z-Score of 1.59 (distressed), revenue growth of +11.8% YoY.

Neutral

Analyst Consensus

Hold

Wall Street consensus estimates — not a PMP forecast · Updated Aug 31, 2026

Analyst Recommendations43 analysts · 2026-08-01
6
15
19
2
Strong Buy 6Buy 15Hold 19Sell 2Strong Sell 1

Recent Market Moves

See all AMGN moves →
DateSessionPriceMoveZ-Score
Aug 5Regular$403.38+3.43%2.28
Aug 5After-hours$409.20+4.92%3.28
Amgen Inc (AMGN) Valuation & P/E History →Amgen Inc (AMGN) Financial Statements →
Share:

Explore More Stocks

AAPLMSFTNVDAGOOGLAMZNMETATSLAJPMWMTVView all stocks →